April 05, 2016
Wellesley, Mass., April 05, 2016 – In today’s life science industry, the popularity of genome editing technology is rising quickly. BCC Research reveals in its new report the growth associated with technologies and related applications for precise genome editing has exploded in the past two years, including the breakthrough emergence of CRISPR/Cas editing technology.
Genome editing is a type of genetic engineering technologies where DNA is inserted, replaced or removed from a genome by using artificially engineered nucleases. Genome editing is a logical next step to the next-generation sequencing technologies and functional genomics studies in understanding and manipulating genes.
Global market revenues, which reached $395 million in 2015, should reach over $2 billion by 2020, reflecting a five-year compound annual growth rate (CAGR) of 38.9%. While all regional markets will experience a fast growth at slightly different rates, the U.S. market, which accounted for about 40% of the global genome editing market in 2014 and 2015, will continue leading the industry with an estimated $806 million in 2020 and five-year CAGR of 39.8%.
Recent years of breakthroughs in biotechnology, including next-generation DNA sequencing technologies, have paved the way for a more precise technology that could manipulate any DNA sequence, even only one single DNA base, in living cells or organisms in a faster, simpler, cheaper and more specific manner. While gene editing technology has existed since around 2005, the methods that use meganucleases, ZFNs and TALENs were complicated, slow and expensive. CRISPR/Cas9 technology, which scientists began to use in human cells around 2013, has impressed researchers with its low cost and eases of use.
Since the emergence of the CRISPR/Cas genome editing technology, the field of genome editing has grown rapidly, impacting many aspects such as basic research, drug discovery and development, clinical applications, and breeding technologies. The exponential growth of the market also stems from its rapid expansion into many other application areas such as non-transgenic breeding, the food industry, the renewable energy industry, drug discovery and development, and clinical therapies for a variety of genetic diseases.
“CRISPR/Cas9 is widely acknowledged to be a game-changer because of the speed, simplicity and specificity with which edits can be carried out,” says BCC Research analyst Mike Fan. “This technology also allows researchers to make multiple edits at one time. Due to its wide range of potential applications, CRISPR/Cas9 has become not only a ‘hot’ research and development area, but also a hot topic of public discussion and debate, particularly because it may one day be used to make edits to human germ lines, which could pass to next generations. In the pharmaceutical industry, drug makers are collaborating closely with genome editing specialized companies to speed the technology forward to clinic use.”
Genome Editing: Technologies and Global Markets (BIO146A) analyzes the industry by technology, by type, and by end-user application. The report examines emerging applications, trends, region, industry, application, product and type, technology, and end-user. Analyses of global market drivers and trends, with data from 2014, 2015, and projections of CAGRs through 2020 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.
Genome Editing: Technologies and Global Markets( BIO146A )
Publish Date: Mar 2016
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.